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Alemtuzumab, ﬂudarabine, and melphalan reduced intensity
conditioning regimens are increasingly used for the he-
matopoietic cell transplantation of pediatric and young adult
patients with non-malignant diseases. Data regarding large
patient groups are limited. We retrospectively analyzed the
outcomes of 206 patients with primary immunodeﬁciencies,
metabolic diseases, and non-fanconi anemia marrow failure
disorders who underwent 210 RIC HCT procedures at Cin-
cinnati Children’s Hospital. Ninety-seven percent of patients
engrafted. Mixed donor and recipient chimerism developed
in 46% of patients. The risk was highest in patients who
received proximal or higher dose/kg alemtuzumab schedules
(all HR>2, all p<0.05) or cord blood grafts (HR 3.122, CI
1.236-7.888, p¼ 0.016). Patients with marrow failure were
protected against mixed chimerism (HR 0.208, CI 0.061-
0.709, p¼0.012). The overall cumulative incidences of grades
II-IV and III-IV acute GHVDwere 25% (CI 20-32%) and 18% (CI
14%-25%). Five percent of patients required re-trans-
plantation. One-year survival without re-transplantationwas
75% (CI 69-81%). Only 2 deaths were related to acute toxic-
ities; themajority were related to infections. Age, HLAmatch,
and grades III-IV acute GVHD impacted survival. Despite the
high incidence of mixed chimerism, alemtuzumab, ﬂudar-
abine, and melphalan RIC HCT offers minimal life-threat-
ening acute toxicities and good outcomes for many patients.313
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Cincinnati, OHIntroduction: Alemtuzumab, ﬂudarabine, and melphalan
reduced intensity conditioning (RIC) regimens are increas-
ingly used for pediatric patients with non-malignant dis-
eases. We have previously reported that the incidences of
acute graft versus host disease (GVHD) andmixed chimerism
are both inﬂuenced by the timing and dose of alemtuzumab.
We speculated that these effects were due to variations in
peri-transplant levels of alemtuzumab and resultant differ-
ences in extent of graft T cell depletion.
Hypothesis: We hypothesized that low or absent levels of
alemtuzumab would result in elevated risk for acute GVHD
but low risk of mixed chimerism, and that high levels of
alemtuzumab would result in low risk of acute GVHD but
increased risk of mixed chimerism.
Methods: We measured alemtuzumab levels on the day of
graft infusion +/- 3 days in 90 patients who received an
alemtuzumab, ﬂudarabine, and melphalan RIC regimen. We
created cumulative incidence curves to compare the in-
cidences of acute GVHD grades II-IV and mixed chimerism in
patients with alemtuzumab levels of 0.1mg/mL or less versus
0.2mg/mL or greater. We used cause-speciﬁc Cox hazard
regression to model the risks of acute grades II-IV GVHD or
mixed chimerism (deﬁned as whole blood donor chimerism
of less than 95% on two or more consecutive occasions)
taking into account the covariates of age, diagnosis, HLA
Match, graft source, and alemtuzumab level (mg/mL,
continuous variable). All computations were done using R
(The R Foundation for Statistical Computing, Vienna,
Austria). Final models were selected using stepwise selec-
tion. Statistical signiﬁcance was considered for p<0.05.
Results: The cumulative incidence of acute GVHD grades II-
IV was 48% in patients with alemtuzumab levels of 0.1 mg/mL
or less, and 18% in patients with levels of 0.2mg/mL or greater
(p<0.001). The cumulative incidence of mixed chimerism
was 34% in patients with alemtuzumab levels of 0.1 mg/mL or
less, and 48% in patients with levels of 0.2mg/mL or greater
(p¼0.24). In multivariate analysis, we found that alemtuzu-
mab level was the only signiﬁcant factor associated with the
risks of acute grades II-IV GVHD and mixed chimerism.
Increasing levels of alemtuzumab decreased the risk of
grades II-IV acute GVHD (HR 0.495, CI 0.282-0.867, p¼0.014).
Conversely, increasing levels of alemtuzumab increased the
risk of mixed chimerism (HR 1.169, CI 1.033-1.324, p¼0.014).
Receipt of a cord blood graft also inﬂuenced the risk (HR
4.134, p¼0.068) but did not reach statistical signiﬁcance,
perhaps due to small sample size.
Conclusion: We conclude that peri-transplant levels of
alemtuzumab dictate the risks for acute GVHD and mixed
chimerism. Detailed pharmacokinetic studies are needed to
optimize and individualize alemtuzumab dosing for pediat-
ric patients in order to minimize these complications.314
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Background: Myeloablative conditioning regimens used for
hematopoietic stem cell transplant (HSCT) are known to
affect endocrine function, most commonly causing primary
